defines the lumen in blood vessels, airways, uterus, and bladder. An abnormal increase in smooth muscle tone has been implicated in the pathogenesis of hypertension, cardiogenic shock, and other motility-related disorders (1, 2) . Relaxation of the smooth muscle can result from the increase of intracellular cAMP and cGMP generated by the activation of adenylyl cyclases and guanylyl cyclases, respectively (3) (4) (5) (6) (7) (8) . The mechanism by which cyclic nucleotides (cAMP and cGMP) could relax the smooth muscle is believed to involve the inhibition of intracellular free Ca 2ϩ concentration as a result of activating cyclic nucleotide-dependent protein kinases (9) . However, the molecular target for the action of cyclic nucleotide-dependent protein kinases (PKA 1 and PKG) in regulating intracellular Ca 2ϩ signaling is unclear.
Phosphoinositide-specific phospholipase C (PLC) is a family of key enzymes in the generation and regulation of intracellular Ca 2ϩ signaling, in cell growth, and differentiation (10) . Molecular cloning has identified 10 mammalian PLC isozymes that can be grouped into three subfamilies (PLC-␤, PLC-␥, and PLC-␦) on the basis of their size, amino acid sequences, domain structure, and activation mechanisms (11, 12) . The various PLC enzymes appear to be activated by different receptors and mechanisms. The PLC-␥ subfamily (␥ 1 and ␥ 2 ) is directly phosphorylated and activated by tyrosine kinase-dependent signaling pathways (12) . The four isozymes of PLC-␤ are activated to various extents by the G␣ q subfamily of G-proteins that couple seven transmembrane receptors to intracellular signaling pathways (13) (14) (15) (16) (17) (18) . Specific activation of PLC-␤2 and PLC-␤3 by the G-protein ␤␥ subunits of the G␣ i/o family of G-proteins has also been reported (19 -21) . Therefore, functionally distinct G-proteins could selectively couple different receptors to PI hydrolysis and intracellular calcium release in the same cell.
There is a wide range of interactions, both between homologous signaling pathways and between heterologous systems (22) (23) (24) (25) . These interactions provide a mechanism that allows G-protein-coupled pathways to influence each other's function and to modulate multiple receptor signaling pathways. For example, there is increasing evidence for a physiological interaction between the PI and cAMP signaling pathways. Both IP 3 and diacylglycerol, products of PLC activation, affect cAMP formation. Calcium mobilized from intracellular stores by IP 3 * This work was supported in part by a Scientist Development grant from the National American Heart Association, a Basil O'Connor Starter Scholar Research award from the March of Dimes Birth Defects Foundation (to M. L.), and National Institutes of Health Grant HD09618 (to B. M. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
ʈ To whom correspondence should be addressed forms a complex with calmodulin. Ca 2ϩ -calmodulin can directly bind to certain forms of adenylyl cyclases to activate them (26, 27) . Diacylglycerol can also activate protein kinase C that attenuates or potentiates hormone-induced cAMP accumulation in different cell types. On the other hand, there are also numerous reports that the hydrolysis of phosphatidylinositol 4,5-bisphosphates (PIP 2 ) is regulated by cAMP and cAMP-dependent protein kinase (PKA). The effects of cAMP on agoniststimulated phosphatidylinositide production range from stimulation to inhibition. cAMP or agents that stimulate production of cAMP (forskolin, prostaglandins E1 and E2, theophylline, prostacyclin, and ␤-adrenergic agents), inhibit phosphatidylinositide breakdown and intracellular Ca 2ϩ mobilization in a number of cells and tissues (3, 5, 28 -38) . However, the molecular mechanism by which the cAMP pathway regulates the PIP 2 metabolism and intracellular Ca 2ϩ mobilization is poorly understood. Our recent work (22, 39) , together with others (37), has suggested that PKA could phosphorylate G-protein-activated phospholipase C isozymes, regulating the G-protein-mediated intracellular Ca 2ϩ signaling. Ca 2ϩ and nitric oxide (NO) work together in the control of cell homeostasis. NO has been recognized to account for the activities of the endothelial-derived relaxing factor by increasing intracellular cGMP concentration. In a number of cells, nitric oxide and atrial natriuretic factor inhibited the release of intracellular Ca 2ϩ from internal storage sites. The inhibitory effects of these agents appear to be mediated by increasing intracellular cGMP and by activating cGMP-dependent protein kinases (6, 9, 40 -46) . Potential PKG phosphorylation targets of intracellular Ca 2ϩ signaling pathway include phospholipase C, G-proteins, Ca 2ϩ -ATPase, phospholamban, IP 3 receptor ion channels, and myosin phosphatase (47) . However, the molecular mechanism of PKG phosphorylation in mediating intracellular Ca 2ϩ release has not been defined. In most cases, the physiological targets of PKG phosphorylation remain to be identified, and their function needs to be clarified. Knowledge of the molecules involved in the regulation of intracellular Ca 2ϩ by cGMP-dependent protein kinase could be of great importance in pharmacology (48) . For example, the effect of the popular drug, Viagra (sildenafil), is to increase intracellular cGMP concentration and lower intracellular Ca 2ϩ levels via inhibiting a specific phosphodiesterase in the vascular smooth muscle. In other words, Viagra achieves its pharmacological effects of relaxing the vascular smooth muscle through the increase of intracellular cGMP and possibly cGMP-dependent protein kinase (9) . However, the molecular mechanism on how an increase in cGMP affects intracellular Ca 2ϩ and, consequently, the relaxation of the vascular smooth muscle is still under active investigation. In this report, we demonstrate that G-protein-activated PLC-␤2 and PLC-␤3 are directly phosphorylated by PKG in vitro with purified proteins and in vivo with metabolic labeling. Phosphorylation of PLC blocks the activation of the proteins by G-protein subunits. Furthermore, we identified two serine residues (Ser 26 and Ser
1105
) as the PKG phosphorylation sites in PLC-␤3. Mutation of these two sites completely abolished the phosphorylation of the protein by PKG and the inhibitory effect of PKG on the activation of PLC-␤3 by G-protein subunits. Therefore, these data define a potential cross-talk mechanism between G-protein-mediated intracellular Ca 2ϩ release and the cGMP/PKG signaling pathway. (50) . Briefly, the aorta was incubated in collagenase (1.5 mg/ml) for 10 min at 37°C before removing the adventitia. The smooth muscle cells were maintained in DMEM with 10% fetal calf serum, 100 units/ml penicillin, 100 g/ml streptomycin, and 0.2 mM glutamine. The cells were grown to confluence and used until the third passage to prevent the loss of endogenous PKGs. Nearly confluent smooth muscle cells (10-cm dish) were labeled with [ 32 P]orthophosphate (0.33 mCi/ml) in phosphate-free DMEM containing 10% dialyzed fetal calf serum for 6 h. After stimulation with the membrane-permeable cGMP analogue, 8-pCPT-cGMP (100 -200 M), cells were lysed in ice-cold lysis buffer containing a mixture of protease and phosphatase inhibitors (37) . Cell extracts were centrifuged at 15,000 ϫ g for 10 min at 4°C. Proteins immunoprecipitated with specific anti-PLC-␤3 antibody were separated on a 7.5% SDS-PAGE and analyzed by autoradiography. The amount of PLC-␤3 protein was normalized for sample loading by Western blot.
EXPERIMENTAL PROCEDURES

Materials
Cell Culture, Transfection, and PLC Activity Assays-COS-7 cells were cultured and transfected as described previously (22) . Briefly, COS-7 cells (1 ϫ 10 5 cells per well) were seeded in 12-well plates in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum a day before transfection. The total amount of DNA in all transfections was 1-1.2 g per well. The cytomegalovirus vector, pCIS, encoding ␤-galactosidase was used to maintain the amount of DNA constant and the amount of a particular cDNA in each set of experiments equal. cDNAs were mixed with LipofectAMINE (Life Technologies, Inc.) in serum-free Opti-MEM (Life Technologies, Inc.), and cells were transfected for about 5 h. 24 h post-transfection, cells were washed with phosphate-buffered saline (PBS) and incubated in 0.5 ml of inositol-free DMEM medium containing 10 Ci ml Ϫ1 of myo-[2-3 H] inositol (Amersham Pharmacia Biotech) and 10% dialyzed fetal bovine serum. 24 h later, cells were washed with PBS and incubated in inositol-free medium containing 10 mM LiCl for 30 min at 37°C. For activation cGMP-dependent protein kinases, 100 M 8-pCPT-cGMP was added to the inositol-free LiCl medium. The cells were lysed by adding ice-cold 10 mM formic acid and incubated on ice for 30 min. Then the lysate was neutralized with 15 mM NH 4 OH. Total inositol phosphates were separated by an anion exchange column (AG 1-X8, Bio-Rad) as described. The eluted inositol phosphates was mixed with 10 ml of scintillation mixture (BCS; Amersham Pharmacia Biotech) and counted in a liquid scintillation counter.
RESULTS
Phosphorylation of PLC-␤ by PKG in Vitro and in Vivo-
We have shown previously that PKA can directly phosphorylate PLC-␤2 and PLC-␤3, blocking the activation of the enzymes by G-protein subunits (22) (39). On the other hand, direct phosphorylation of PLC-␤ isozymes by cGMP-dependent protein kinases has not been reported, although it has been known that an increase in intracellular cGMP can inhibit the hydrolysis of phosphatidylinositide and the release of intracellular Ca 2ϩ . In order to understand the regulation of G-protein-mediated PLCCa 2ϩ signaling by pathway coupled to intracellular cGMP, we extended our studies on the phosphorylation of PLC-␤ isozymes by PKG both in vitro and in the smooth muscle cells. As shown in Fig. 1A , incubation of purified PLC-␤ isozymes with purified PKG demonstrated that both PLC-␤2 and PLC-␤3 are good substrates for PKG, whereas PLC-␤1 was not phosphorylated by the kinase under the same conditions. To quantify PKGstimulated PLC-␤3 phosphorylation, purified PLC-␤3 was phosphorylated by PKG in vitro. Fig. 1B shows the time-dependent incorporation of 32 P into PLC-␤3 protein catalyzed by PKA and PKG. Compared with the phosphorylation of PLC-␤3 by PKA (Fig. 1B, top) , PKG phosphorylation is slower and approached a plateau in about 60 min. Estimation of the K m value for PKA is about 1 M, whereas the K m value for PKG is somewhat higher, ϳ12 M when assayed with different concentrations of purified PLC-␤3 protein. A maximum ratio of 1.3 mol of phosphate/mol of PLC-␤3 was determined by a filter binding assay at the 60-min incubation point, suggesting two possible phosphorylation sites in PLC-␤3 protein.
There are three different isoforms of PKG that differ in their sequences, distribution, and membrane association (51) . To examine whether all three isozymes of PKG can phosphorylate PLC-␤ proteins, we phosphorylated overexpressed PLC-␤3 in the presence of PKGI␣, PLGI␤, and PKGII, and we then immunoprecipitated PLC-␤3 using specific anti-PLC-␤3 antibodies. As shown in Fig. 1C , PLC-␤3 was phosphorylated by all three isozymes of PKG in our in vitro phosphorylation assays.
To test the notion that PLC-␤2 and PLC-␤3 are physiological targets of cGMP-dependent protein kinases in the cell, we further analyzed whether activation of PKG can directly phosphorylate PLC-␤ isoforms in cells expressing these proteins. Cell extracts from cultured smooth muscle cells were incubated in the presence of [␥- 32 . Then the phosphorylated proteins were separated by SDS-PAGE and visualized by autoradiography. EGTA (2 mM) was included in all reactions to remove calcium, an activator of proteases and protein kinase C. B, PLC-␤2 and PLC-␤3 were phosphorylated in smooth muscle cell extracts stimulated with 8-Br-cGMP (1 M). The phosphorylated cell extracts were immunoprecipitated with specific anti-PLC-␤2 and PLC-␤3 antibodies. Precipitated PLC-␤2 and PLC-␤3 proteins were separated by SDS-PAGE and visualized by autoradiography. The specificity of the anti-PLC-␤2 and anti-PLC-␤3 antibodies was tested in vitro with purified PLC proteins and in cell lysates. C, in vivo 32 P labeling of PLC-␤3 isolated from cultured smooth muscle cells. VSMCs from rat aorta between the third and fifth passage were used so that endogenous PKG can be preserved. Western blot shows that PKG can be detected up to passage level 7 in the VSMCs. The cells were metabolically labeled with [ 32 P]orthophosphate in phosphate-free DMEM in the presence or absence of PKG activator, 8-pCPT-cGMP (100 M) for 3-4 h. Then the PLC-␤3 was immunoprecipitated by specific anti-PLC-␤3 antibody, and the proteins were separated on SDS-PAGE. Phosphorylated PLC-␤3 was visualized by autoradiography. Similar results were obtained from three independent experiments. As a control, we did not see any specific band corresponding to the size of PLC-␤ when precipitated with a preimmune serum. Bottom panel, Western blot of PLC-␤3 using specific anti-PLC-␤3 antibody, demonstrating an equal amount of protein was loaded in the gel.
phosphorylation intensities of 130 -140-kDa proteins. Immunoprecipitation with specific antibodies against PLC-␤2 and PLC-␤3 indicated that both proteins are phosphorylated by the stimulation of 8-Br-cGMP (Fig. 2B ). Together these data suggested that PLC-␤ proteins could be one of the physiological targets upon stimulation of smooth muscle cell extracts by intracellular cGMP.
To confirm that PLC-␤3 is phosphorylated upon stimulation of increased cGMP in the cell, cultured smooth muscle cells before passage level 5 were metabolically labeled with [ 32 P]orthophosphate. The expression of PKG in VSMCs before passage level 8 was confirmed by Western blot using specific anti-PKG antibodies. PLC-␤3 protein was immunoprecipitated by a specific anti-PLC-␤3 antibody after labeling of the cell. Stimulation of PKG by the selective activator, 8-pCPT-cGMP, substantially increased the 32 P incorporation into PLC-␤3 protein (Fig. 2C) , indicating that PLC-␤3 is a potential physiological target of cGMP-dependent protein kinases in the cell.
Inhibition of G-protein-activated PLC-␤3 by PKG Isoforms-To test whether cGMP and PKG are involved in the agonist-stimulated and G-protein-mediated PLC signaling pathway, we constructed mammalian expression plasmids that encode the three different PKG isoforms. Then we reconstituted the G-protein-activated PLC-Ca 2ϩ signaling pathway in COS-7 cells by introducing cDNAs encoding G-protein subunits, PLC-␤, and PKGs into the cells. Specific activation of PLC-␤3 by G-protein ␤␥ subunits was measured by the release of inositol phosphates (IP 3 ) (Fig. 3A) . In the presence of PKG isozymes, the activation of PLC-␤3 by G-protein ␤␥ subunits was substantially reduced upon stimulation of PKGs by the membrane-permeable cGMP analogue, 8-pCPT-cGMP (Fig.  3A) . Since PLC-␤3 is also activated by G␣ q , we examined the PI turnover in COS-7 cells transfected with PLC-␤3 and G␣ q protein in the presence or absence of PKG. As shown in Fig. 3B , transfection of empty vector, G␣ q , PLC-␤3, or PKG alone had little effect on basal PI turnover. Cotransfection of G␣ q with PLC-␤3 increased the production of inositol phosphates by approximately 5-fold. On the other hand, cotransfection and activation of PKG inhibited more than 60% of the activation of PLC-␤3 by G␣ q .
To examine whether the agonist-induced IP 3 synthesis is indeed inhibited by the activation of PKG, we measured the production of IP 3 induced by activation of the M1 muscarinic receptor in COS-7 cells in the presence or absence of overexpressed PKG. COS-7 cells were transfected with the M1 muscarinic receptors coupled to PLC-␤ through G␣ q protein. As shown in Fig. 3C , when the M1 receptor was transfected in COS-7 cells and stimulated with its ligand, carbachol, the production of [ 3 H]IP 3 was increased about 5-6-fold. Cotransfection and activation of the PKG isoforms inhibited the agonist-stimulated IP 3 release by 30 -40% in COS-7 cells (Fig. 3C) . Since COS-7 cells contain multiple PLC-␤ isoforms (␤1, ␤2, and ␤3), the observed inhibitory effects may underestimate the effects of PKG on the regulation of receptor-stimulated Gprotein-coupled IP 3 signaling in the cell. Together, these data suggest that activation of PKG could phosphorylate PLC and inhibit the agonist-induced IP 3 production in the cell.
PKG Phosphorylates Distinct Peptides in PLC-␤3
Compared with PKA Phosphorylation-To examine whether PKG phosphorylates PLC-␤3 at the same sites as PKA phosphorylation, we phosphorylated purified PLC-␤3 protein with sequential addition of the two kinases (PKA and PKG) in the presence of non-radioactive ATP first and then of [␥-32 P]ATP. Initial phosphorylation of PLC-␤3 by PKA in the presence of non-radioactive ATP has limited effect on the subsequent phosphorylation of the protein by PKG (Fig. 4A) . However, initial phosphoryla- tion of PLC-␤3 by PKG in the presence of non-radioactive ATP prevents subsequent phosphorylation of the protein by PKA (Fig. 4B) . These results indicate that PKG not only shares one or more phosphorylation sites in PLC proteins with PKA, but also has unique phosphorylation sites that are not blocked by initial PKA phosphorylation of the protein in the presence of non-radioactive ATP. On the other hand, the PKA phosphorylation sites in PLC-␤ are shared by PKG, as shown by the inhibitory effect of initial PKG phosphorylation on the subsequent PKA phosphorylation of the PLC-␤ protein (Fig. 4B) .
To understand further the phosphorylation pattern of PLC-␤ protein, we compared the phosphopeptide mapping of PLC-␤3 protein phosphorylated by either PKA or PKG. As shown in Fig. 5 , phosphopeptide mapping of in vitro phosphorylated PLC-␤3 by PKA (Fig. 5A) and PKG (Fig. 5B ) digested by trypsin showed largely similar patterns of peptide phosphorylation. However, compared with PKA phosphorylation, PKG has a unique phosphopeptide at position 1 in Fig. 5B . Both PKG and PKA have favored phosphorylation sites (position 3 for PKG and position 2 for PKA in Fig. 5, A and B) . Together, these data suggest that PKG phosphorylates at least one unique site in PLC-␤3 protein compared with PKA.
Identification of the PKG Phosphorylation Sites in PLC-␤3-
Detailed characterization of the phosphorylation sites in PLC-␤ isoforms is an essential step toward understanding the mechanism of PLC-␤ activation and regulation by cGMP-dependent protein kinase. In this report, we focus on the identification of phosphorylation sites in PLC-␤3. Three putative PKG phosphorylation sites (Ser 26 , Ser 474 , and Ser 1105 ) were found in human PLC-␤3 (Fig. 6A) (52) . To determine which serine residue is phosphorylated in the protein, we purified a mutant PLC-␤3 protein (S1105A) from insect Sf9 cells. Mutation at this site abolished the phosphorylation of PLC-␤3 by PKA (Fig. 6B) , consistent with the result reported previously (39) . However, the phosphorylation of purified mutant PLC-␤3 protein (S1105A) by PKG was only reduced by ϳ30% compared with the phosphorylation of wild-type PLC-␤3 protein (Fig. 6C) , suggesting PKG also phosphorylates additional sites, consistent with the results of phosphopeptide mapping.
To identify the remaining phosphorylation sites, we made three single mutations at Ser 26 , Ser 474 , and Ser 1105 and one double mutation (S26A,S1105A). cDNAs corresponding to the wild-type and the mutant PLC-␤3 were cotransfected into COS-7 cells, and the proteins were isolated and purified by immunoprecipitation using specific antibodies against PLC-␤3. Then the purified proteins were phosphorylated in vitro using purified PKG. As shown in Fig. 6D , wild-type PLC-␤3 was a good substrate of PKG, whereas mutation at Ser 26 26 and Ser 1105 of PLC-␤3 are not conserved among the PLC enzymes. Therefore, the mode of regulation between different PLC-␤ isoforms (␤1, ␤2, ␤3, and ␤4) could vary.
To confirm our observation that serines 26 and 1105 are functional phosphorylation sites in the protein, we cotransfected the mutant proteins with G-protein subunits into COS-7 cells and measured the activation of the mutant proteins in the presence of activated PKG. As shown in Fig. 7, A and B ) had no effect on the activation of PLC-␤3 by G-protein subunits in COS-7 cell transfection assays. However, unlike the wild-type PLC-␤3, cotransfection and activation of PKG no longer elicited inhibitory effects on the activation of the double mutant PLC-␤3 protein (S26A,S1105A) by G␣ q (Fig. 7A) and G␤␥ subunits (Fig. 7B ). Mutation at either Ser 26 or Ser 1105 alone had very limited effect on the inhibition of PKG, whereas mutation at Ser 474 has no effect on the inhibition of PLC by PKG (Fig. 7,  A and B) . Together, these data indicate that the two serine residues (Ser 26 and Ser 1105 ) play a key role in the regulation of PLC-␤3 enzyme by cGMP-dependent protein kinase.
DISCUSSION
In the vascular smooth muscle, nitric oxide (NO) has been recognized to account for the activities of the endothelially derived relaxing factor by increasing intracellular cGMP concentration via the activation of guanylyl cyclases. NO inhibits IP 3 generation and intracellular Ca 2ϩ mobilization by increasing the intracellular cGMP concentration. The downstream target for cGMP is believed to be the PKGs, which mediate the effects of cGMP in a number of cells or tissues, including the vascular smooth muscle and platelets (9, 31, 40, 51, 53) . Whereas an increase in cGMP level correlates well with a decrease in intracellular Ca 2ϩ concentration and the relaxation of the vascular smooth muscle in a time-and concentration-dependent manner, the molecular mechanisms for cGMP-PKG to regulate intracellular Ca 2ϩ signaling are not well defined. In this report, we demonstrate that PLC-␤2 and PLC-␤3 are good substrates for cGMP-dependent protein kinases, whereas PLC-␤1 was not phosphorylated in the same assays. These results correlate well with our cell transfection assays in which activation of PLC-␤2 and PLC-␤3 by G-protein subunits is inhibited by coexpression and activation of PKG isozymes (regulation of PLC-␤2 by PKG has not been shown in this paper). By using phosphopeptide mapping and site-directed mutagenesis, we further identified two key phosphorylation sites (Ser 26 and Ser 1105 ) for the regulation of PLC-␤3 by PKG. Mutation at these sites of PLC-␤3 dramatically reduced the inhibitory effect of PKG on the activation of PLC by G-protein and the phosphorylation of the PLC protein by PKG. These results indicate that PKG can directly phosphorylate PLC isozymes (␤2 and ␤3) and regulate the activation of receptor-mediated G-protein-coupled phosphatidylinositol (PI) turnover and intracellular Ca 2ϩ release. There are four isozymes of phospholipase C-␤ that are activated to various extents by G␣ q proteins, which account for the pertussis toxin-resistant activation of PLC and intracellular Ca 2ϩ increase. It has been shown that the C terminus of PLC-␤1 is critical for the activation of the enzyme by G␣ q (52, 54) . Deletion studies have identified a P box region (Thr 903 to Gln 1030 ) and a G box domain (Lys 1031 to Leu 1142 ) in the C terminus of PLC-␤1. The P box of PLC-␤1 is important for the association of PLC-␤1 with cell membrane and the activation of the enzyme by G␣ q , whereas the G box domain is involved in the interaction with G␣ q subunits (52) . We previously showed that phosphorylation of serine residues at the C-terminal domains of PLC-␤ by PKA inhibited the G-protein-mediated PLC-␤ activity (22, 39) . Phosphorylation at Ser 1105 of PLC-␤3 accounts for the inhibitory effect of PKA on the activation of the protein by G␣ q (39) . In this report, we shown that PKG also phosphorylated Ser 1105 in PLC-␤3. Phosphorylation of the protein at serine 1105 could potentially reduce or block the association of PLC-␤ with G-protein ␣ subunit.
Specific activation of PLC-␤2 and PLC-␤3 by G-protein ␤␥ subunits accounts for the pertussis toxin-sensitive PLC activation and Ca 2ϩ release. The sites of interaction with G-protein ␤␥ subunits in PLC-␤3 are located in both the N-terminal domain and in the catalytic X domain of the PLC-␤ protein (55) (56) (57) . The N-terminal first 100 amino acids are predicted to form a pleckstrin homology (PH) domain (58) . The PH domain isolated from PLC-␦ binds to PIP 2 and IP 3 , and deletion of the PH domain from PLC-␦ inhibited anchoring of the protein to PIP 2 -containing membrane but did not inhibit catalysis (59 -61) . The role of PH domain in PLC-␤ isoforms is not clear. Recent data indicate that a fragment encompassing the Nterminal PH domain bound to G-protein ␤␥ subunits, and the PH domain of PLC-␤2 determines the binding and activation by G-protein ␤␥ subunits (55, 62) . Therefore, phosphorylation of Ser 26 in PLC-␤3 by cGMP-dependent protein kinase could affect the interactions of the PLC protein with either G-protein ␤␥ subunits or phospholipid in the membrane or with both. We are in the process of testing this hypothesis.
Nitric oxide and cyclic GMP have emerged recently as a principal focus in signal transduction, playing important regulatory roles in smooth muscle relaxation and proliferation, inhibition of platelet aggregation, neutrophil degranulation, and initiation of visual signal transduction. A number of intracellular proteins are activated by an increase in intracellular cGMP. Examples include cGMP-dependent protein kinases (PKGs), cyclic nucleotide-gated ion channels, cGMP-binding phosphodiesterases, PKA, and myosin phosphatase (47, 63, 64) . In vascular smooth muscle cells, platelets, and neuronal cells, nitric oxide and atrial natriuretic factor inhibited the intracellular Ca 2ϩ release induced by activation of G-proteincoupled receptors. The inhibitory effects of these agents appear to be mediated by increasing intracellular cGMP and by activating cGMP-dependent protein kinases. Three different
FIG. 8. Proposed model for the regulation of G-protein-activated PLC-Ca
2؉ by signaling pathway coupled to cGMP-dependent protein kinase. Receptors (R) coupled to both G␣ q and G␣ i /␤␥ can activate PLC-␤ isozymes, leading to the production of IP 3 and diacylglycerol (DAG), key second messengers in the release of intracellular Ca 2ϩ and the activation of protein kinase C, respectively. Reagents, such as nitric oxide (NO), atrial natriuretic peptide (ANP), and brain natriuretic peptide (BNP), can stimulate guanylyl cyclases, leading to the increase of intracellular cGMP from GTP. One of the functions of cGMP is to activate cGMP-dependent protein kinases that can directly phosphorylate and inhibit G-protein-activated PLC-␤ activity, blocking the hydrolysis of inositol phosphates and the release of intracellular Ca 2ϩ and, consequently, regulating cellular functions.
isozymes of cGMP-dependent protein kinases (PKGs), PKGI␣, PKGI␤, and PKGII, have been cloned and characterized (51) (64) . PKGI␣ and -I␤ are alternative spliced variants, highly expressed in the vascular and gastrointestinal smooth muscle, lung, cerebellum, platelets, and heart (51, (65) (66) (67) (68) . The PKGII isoform is a membrane-associated protein, expressed in secretory epithelium and in various regions of the brain (69 -71) . Our in vitro studies have shown that all three PKG isoforms can directly phosphorylate PLC-␤3 and PLC-␤2. Cotransfection and activation of the kinases in COS-7 cells decreased the G-protein-activated IP 3 release, a result of blocking PLC-␤ activation. The precise physiological role of PLC-␤ phosphorylation by cGMP-dependent protein kinases may depend on the localization of the two proteins in the cell or tissue. A recent report demonstrates that cGMP kinase I␤ can form signaling complex with IP 3 receptor and IRAG (an IP3R-associated cGMP kinase substrate) in microsomal smooth muscle membrane to regulate intracellular calcium (72) . The observation that PLC-␤3 and PKGs are immunoprecipitated together suggests an interesting possibility that these proteins may form signaling complex in the cell. The notion that PLC may form signaling complex with PKG and other molecules is under investigation.
In summary, this work provides the first evidence that Gprotein-activated PLC-␤ isozymes are the potential physiological target for signaling pathways coupled to cGMP and cGMPdependent protein kinases. A working model (Fig. 8) is proposed in which nitric oxide and other peptides, such as atrial natriuretic peptide and brain natriuretic peptide, stimulate guanylyl cyclases, leading to the production of cyclic GMP and the activation of cGMP-dependent protein kinases. Phosphorylation of PLC isozymes by PKG blocks the activation of the enzymes by G-protein subunits, resulting in the inhibition of agonist-stimulated intracellular Ca 2ϩ release and the regulation of cellular functions.
